The agency issued a PDUFA target action date of June 14, 2027.
|Articles|February 6, 2020
Dr. Mara Holton discusses LUGPA's recent policy victories, upcoming challenges
Dr. Holton, vice chair of LUGPA's Health Policy Committee, spoke with Urology Times at the 2019 LUGPA annual meeting in Chicago.
Advertisement
Mara R. Holton, MD, vice chair of LUGPA's Health Policy Committee, spoke with Urology Times at the 2019 LUGPA annual meeting in Chicago.
Advertisement
Related to this article
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Prostate Cancer Case Review: Selecting Radioligand Therapy Candidates
2
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
3
Jeffrey M. Spier, MD, on the evidence for reduced-dose enzalutamide
4
Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC
5